

# Biologics R&D in China: Status and Future Directions

王 鵬 (Simcere)

---

R&D of biologics, particularly therapeutic antibodies, have become a hot area in China, with approximately 20 companies filing IND applications for antibodies over last few years. However, compared with established countries, there exist more significant issues with research, manufacturing and regulatory filing of therapeutic antibodies in China. In this presentation, the status and future directions of therapeutic antibody R&D in China will be discussed.

---